Warning! You won't be able to use the quotation basket until you enable cookies in your Web browser.
Warning! Your Web browser is no longer supported. Please upgrade to a modern browser.

Tumor Markers: Relationship between Clinical Pathology and Molecular Diagnostics/Immunohistochemistry

Email Subscription

Be the first to know about upcoming webinars and join the hundreds that enhance their knowledge with our new videos, articles, and other industry leading content.

CE Credits and Certificates of Attendance are no longer available for webinars more than 12 months old.


This presentation will highlight the use of tumor markers in serum chemistry, and their relationship to the diagnosis and monitoring of patients with malignant disease. Tumor markers are molecules occurring in blood or tissue that are associated with cancer, and whose measurement or identification is useful in patient diagnosis or clinical management. The ideal marker would be a “blood test” for cancer, in which a positive result would occur only in patients with malignancy, would correlate with stage and response to treatment, and that is easily and reproducibly measured. No tumor marker now available has met this ideal, but development and discovery continues in the use of these markers for clinical diagnosis. This presentation will explore the use of common markers such as CA-125, Carcinoembryonic Antigen (CEA), Alpha-Fetoprotein (AFP), CA 72.4, CA 15.3, CA19.9, Prostate Specific Antigen (PSA), and a variety of other enzymes and proteins now in use for the diagnosis and monitoring of malignancy. In addition, future serum tumor markers and the use of gene expression profiles and other information from circulating tumor cells (CTCs) will also be discussed.

Learning Objectives:

  1. An overview of current serum tumors markers, their different classifications, and their use in disease monitoring.
  2. The usage of tumor markers in patient diagnosis and management, in both clinical medicine and immunohistochemistry will be discussed.
  3. A review of future developments in tumor markers and diagnostic methods, including DNA isolation and gene expression profiles of circulating tumor cells.

Leica Biosystems webinars, training presentations and related materials provide general information regarding particular subjects and are not intended to be, and should not be construed as medical, regulatory or legal advice. The views and opinions expressed are the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents.

For the use of any product, the product information guides, inserts and operation manuals of the various products and devices should be consulted. Leica Biosystems and the editors disclaim any liability arising directly or indirectly from the use of devices, techniques or procedures described in these materials.

Copyright © 2019 by Leica Biosystems Richmond Inc. All rights reserved.LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.

Did you like the post? Subscribe for the latest updates!

Be the first to know about upcoming webinars and join the hundreds that enhance their knowledge with our new videos, articles, and other industry leading content.